眼周原发性基底细胞癌分期切除:再切除标本中无残留肿瘤的10年系列研究
英国谢菲尔德一家三级眼整形转诊中心回顾性分析了2007—2017年437例眼周基底细胞癌分期切除病例,初次切除采用3 mm临床清晰边缘。156例切缘接近或受累,其中再切除标本仅29例(18.6%)发现残留肿瘤,122例(78.2%)未见残留肿瘤。平均随访57个月期间2例(1.6%)复发。
要点
- 眼周基底细胞癌分期切除后,切缘接近或受累者再切除标本中多数未见残留肿瘤。
- 再切除标本无残留肿瘤者占78.2%,有残留肿瘤者占18.6%。
- 切缘受累时再切除仍是推荐处理,尤其高危亚型;本研究复发率1.6%。
核心结论
- 初次切除离断的眼周基底细胞癌中相当比例在再切除标本中无残留肿瘤,但切缘受累时再切除仍是推荐处理,尤其高危亚型。
研究设计与样本
- 回顾性研究,纳入英国谢菲尔德三级眼整形转诊中心10年间(2007—2017)437例眼周基底细胞癌分期切除病例,初次切除边缘为3 mm临床清晰边缘。
主要发现
- 437例中156例切缘接近或受累,再切除标本中29例(18.6%)发现残留肿瘤,122例(78.2%)未见残留肿瘤。
- 该人群中最常见生长模式为微结节型(54.1%)和结节型(23.7%),最常见部位为下睑(72.1%)。
- 平均随访57个月(范围1—125个月)期间2例(1.6%)复发。
关键数值与推荐
- 初次切除采用3 mm临床清晰边缘。
- 切缘接近或受累者中,再切除标本残留肿瘤占18.6%,无残留肿瘤占78.2%。
- 微结节型占54.1%,结节型占23.7%,下睑部位占72.1%。
- 平均随访57个月(范围1—125个月),复发2例(1.6%)。
临床怎么用
- 眼周基底细胞癌切缘接近或受累时,再切除仍是推荐处理,尤其高危亚型。
- 再切除标本无残留肿瘤并不少见,初次切除与再切除间期可能存在残留肿瘤清除。
局限性
- 本研究为回顾性单中心研究,再切除后无残留肿瘤的确切机制尚不清楚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The aim is to study staged periocular basal cell carcinoma (BCC) excision in a tertiary oculoplastic referral centre in Sheffield, UK. In particular, we examined patients with close or positive margins and no tumour seen on re-excision to identify demographics and tumour characteristics in this population. METHODS: A retrospective review of medical records of 437 cases of staged periocular BCC excisions over a 10-year period (2007-2017) was carried out. Patients had surgical excision with 3 mm clinically clear margins. Staged excision was performed for all cases included in this study. Standard reconstruction techniques were employed. Histopathology was analysed for tumour type, subtype and stage. RESULTS: Over the 10-year period, of the 437 periocular BCCs, 156 had close or involved margins. Residual tumour was found in 29 (18.6%), whereas in 122 eyelids of 120 patients (78.2%) no residual tumour was identified on histological examination. Micronodular (54.1%) and nodular (23.7%) growth patterns of BCC, as well as lower eyelid location (72.1%), were the most prevalent in this population. Two patients (1.6%) had recurrence of BCC over a mean follow-up of 57 months (range 1-125 months). CONCLUSIONS: A significant proportion of BCCs transected on initial excision show no residual tumour in the re-excision specimens. In the interval between initial excision and re-excision, there may be eradication of the residual tumour. The exact mechanisms for this are unclear, however, and re-excision remains the appropriate recommended course in the presence of involved surgical margins of periocular BCC, particularly when high-risk tumour subtypes are encountered.
引用
- McGrath LA, Meeney A, Currie ZI, et al. Staged excision of primary periocular basal cell carcinoma: absence of residual tumour in re-excised specimens: a 10-year series. Br J Ophthalmol. 2018. PMID: 30181140. doi:10.1136/bjophthalmol-2018-312441
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。